Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function

摘要

This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease.

主权项

1. A method of treatment for Alzheimer's disease, comprising the steps of:
a. selecting a patient having, or at risk of Alzheimer's disease; b. determining in the patient the presence of at least one of the specific genotypes selected from the group consisting of:
i. heterozygosity for A/C of Apolipoprotein E (ApoE) rs405509 at relevant portion shown by SEQ ID NO:21,ii. heterozygosity for G/A of Butyrylcholine esterase (BUCHE) rs1803274 at relevant portion shown by SEQ ID NO:18,iii. homozygosity for adenine of Insulin-like Growth Factor Receptor Precursor (IGF1R) rs2229765 at relevant portion shown by SEQ ID NO:6,iv. homozygosity for thymine of Interleukin-1 beta (IL1B) rs1143627 at relevant portion shown by SEQ ID NO:9,v. homozygosity for cytosine of IL1B rs16944 at relevant portion shown by SEQ ID NO:10,vi. homozygosity for cytosine of Low-density Lipoprotein Receptor (LDLR) rs2738447 at relevant portion shown by SEQ ID NO:24,vii. homozygosity for guanine of LDLR rs7259278 at relevant portion shown by SEQ ID NO:25, andviii. homozygosity for cytosine of LDLR rs1799898 at relevant portion shown by SEQ ID NO:15; and c. administering to the patient having at least one of the specific genotypes in (b) a composition comprising an effective amount of a composition comprising medium chain triglycerides (MCT) of the formula: wherein the R1, R2, and R3 esterified to the glycerol backbone are each independently fatty acids having 5-12 carbon chains.